• Business Development
  • CSR
  • Adverse Event Reporting


Expanding horizon delivering on the promise

  • 2015

    Successfully completed Intial Public Offering

  • 2015

    Acquired a formulation manufacturing facility in the US.

  • 2014

    Clavam crossed Rs. 2,000 million in terms of domestic sales in India.

  • 2014

    Acquired the “Clindac-A” brand in India from Galderma S.A.

  • 2013

    Acquired an API manufacturing facility in the US.

  • 2012

    Acquired an API Manufacturing facility in the US.

  • 2011

    Acquired Enzene, a company engaged in the development of biosimilars in India.

  • 2010

    Acquired Ascend Laboratories, a generic marketing company in the US.

  • 2009

    Acquired Pharmacor Pty Ltd., a generic pharma company in Australia.

  • 2009

    Received our first ANDA approval in US for Amlodipine.

  • 2007

    Filed our first ANDA in the US for the drug Amlodipine.

  • 2006

    Our anti-infective drug Taxim became the first anti-infective drug in the Indian
    pharmaceutical industry to cross Rs. 1,000 million in terms of domestic sales in India.

  • 2003

    Set up our research and development facility for ANDA development at Taloja.

  • 1992

    Established manufacturing facility in Mandva, Gujarat.
    This facility was converted into an API facility in 2005.

  • 1978

    Established our first plant at Taloja, Mumbai

  • 1973

    Alkem Laboratories Limited was incorporated